- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02637349
Polaris Oncology Survivor Transition (POST) System (POST)
The POST's public health impact is likely to be substantial because it will improve cancer survivorship planning, which is currently an important deficiency in cancer care recognized by the Institute of Medicine and the American College of Surgeons.
The POST may have many potential benefits for patients such as:
- improved long-term health outcomes;
- improved psychosocial outcomes and quality of life;
- smoother transitions back into old and new life roles; and
- improved continuity and coordination of care between providers.
Most importantly, the POST's influence may reach beyond the patients it directly serves as it could help scientists and health care providers understand the potential benefits of cancer survivorship planning and how to best design and implement survivorship planning when patients are ending treatment for cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School-Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Confirmed diagnosis of breast cancer (not metastatic)
- A final active treatment appointment scheduled with oncology team
- Able to read or understand English at a 6th grade level
Exclusion Criteria:
- Altered mental status (e.g., psychosis, delirium, disorientation)
- Visual problems preventing them from reading the assessment and reports
- Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain)
- Unable to read or understand English at a 6th grade level
- Characteristics that would prevent adequate follow-up (e.g., lack of a telephone)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: POST SCP
Patient receives Survivorship Care Plan (SCP) after active treatment ends.
It will be discussed with the patient.
SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
|
POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment.
The SCP will be discussed with them.
Patient will be asked about satisfaction with the end of treatment session.
|
Active Comparator: POST TAU
Patient receives treatment as usual (TAU) after active treatment ends.
|
The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure.
They will be asked about their satisfaction with the end of treatment session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Quality of Life
Time Frame: 1,3, 6 months after entering the study
|
Quality of life will be measured at baseline and at the follow-ups using the City of Hope Quality of Life measure.
Improvement in quality of life is the primary goal of survivorship planning.
|
1,3, 6 months after entering the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Confidence in Transitioning to Survivorship
Time Frame: 1,3,6 months after entering the study
|
National Cancer Institute (NCI) and the Institute of Medicine (IOM) have emphasized that SCPs should help improve patients' feelings of preparedness and confidence in managing and understanding the next steps at the end of treatment.
This will be measured at baseline and follow-up sessions using the Confidence in Survivorship Information Questionnaire (CSI).
|
1,3,6 months after entering the study
|
Changes in Depression
Time Frame: 1,3,6 months after entering study
|
Changes in depression will be measured by the Patient Health Questionnaire -9 (PHQ-9).
|
1,3,6 months after entering study
|
Changes in Anxiety
Time Frame: 1,3,6 months after entering study
|
Changes in anxiety will be measured by the General Anxiety Disorder 7-item measure (GAD-7).
|
1,3,6 months after entering study
|
Change in Health care utilization
Time Frame: 6-months after entering the study
|
Participants' medical charts will be reviewed six months after termination of active treatment for frequency and appropriateness of oncology, primary care, and emergency room visits, as well as hospitalizations.
|
6-months after entering the study
|
Change in Patient Satisfaction and Usefulness of SCP
Time Frame: 1,3,6 months after entering the study
|
Patients will be asked to assess their satisfaction with the POST program and with the content and quality of the SCP.
|
1,3,6 months after entering the study
|
Change in Patient Satisfaction with the POST system
Time Frame: 1,3,6 months after entering the study
|
Patients will be asked to assess their satisfaction with the POST system.
|
1,3,6 months after entering the study
|
Change in Provider Satisfaction with the POST system
Time Frame: 1,3,6 months after entering the study
|
Providers will be asked to assess their satisfaction with the POST system.
|
1,3,6 months after entering the study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Erin O'Hea, PhD, University of Massachusetts, Worcester
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2R42CA174048-03 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on POST Intervention
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Seva FoundationQueen's University, Belfast; Indian Institute of Public Health, India; Seva Canada... and other collaboratorsCompletedDiabetic RetinopathyNepal
-
Imperial College LondonCompletedAortic Aneurysm
-
Centre Hospitalier RouffachRecruitingAutism Spectrum DisorderFrance
-
Gazi UniversityAnkara City Hospital Bilkent; Lokman Hekim ÜniversitesiActive, not recruitingLower Extremity FractureTurkey
-
St. John's Research InstituteNational Heart and Lung InstituteCompletedAcute Coronary SyndromeIndia
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); Fox Chase Cancer CenterRecruiting
-
Steba Biotech S.A.ICON plc; International Drug Development InstituteCompletedCancer of the ProstateNetherlands, Spain, France, Germany, United Kingdom, Finland, Italy, Sweden
-
Abramson Cancer Center at Penn MedicineFox Chase Cancer Center; Merck Sharp & Dohme LLC; AstraZeneca; Basser Center for...Recruiting
-
University of Maryland, BaltimoreUniversity of Alabama at Birmingham; University of Maryland, College Park; University...Active, not recruitingHIV/AIDS | Opportunistic Infections | Hospitalization | Transitions of CareZambia